Trevena to Present at the Virtual JMP Securities CNS Forum

CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020.

Presentation Details

About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.   The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please contact:

Investor Contact:Daniel FerryManaging DirectorLifeSci Advisors, LLC[email protected] (617) 430-7576

Company Contact:Bob Yoder SVP and Chief Business OfficerTrevena, Inc.(610) 354-8840

You May Also Be Interested In

• Mix&Match to Launch Professional Hair and Makeup Courses Built on 35 Years of Styling Expertise
• Great Southern Bancorp, Inc. Reports Preliminary Second Quarter Earnings of $1.43 Per Diluted Common Share
• Chambers Ranks Phillips & Associates in 2026 Guide as Firm Sharpens Focus on Workplace Power Dynamics and Relationship Retaliation